Skip to main content

Table 2 Disposition of women randomized to luteal support with progesterone vaginal insert and progesterone in oil

From: Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support

Parameter

PVI

PIO

(n = 53)

(n = 57)

Received luteal phase support

48 (90.6)

50 (87.7)

Underwent embryo transfer

46 (86.8)

49 (86.0)

Biochemical pregnancy*

32 (60.4)

37 (64.9)

Clinical pregnancy

27 (50.9)

29 (50.9)

Ongoing pregnancy

25 (47.2)

28 (49.1)

  1. Values are n (%).
  2. *Positive result on serum β-hCG test 12–14 days after embryo transfer, P = 0.853.
  3. Gestational sac visualized using transvaginal ultrasonography approximately 4 weeks after embryo transfer, P = 1.0.
  4. Fetal heart movements identified using transvaginal ultrasonography at approximately 6 weeks’ gestation, P = 0.851.
  5. PVI, progesterone vaginal insert; PIO, progesterone in oil; β-hCG, beta human chorionic gonadotropin.